January 10, 2018

Case: In re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation
Court: District of Massachusetts, U.S. District Judge Denise J. Casper
Drug: Solodyn, acne medication
Status: Awaiting summary judgment ruling

This multidistrict litigation centralized in 2014 claims that Medicis Pharmaceutical Corp. used a combination of reverse payment settlements with several generics makers under what the purchasers claim was an invalid and unenforceable patent to delay generic competition to Solodyn, an extended-release version of an older antibiotic.

. . .

Case: In re: Lipitor Antitrust Litigation
Court: U.S. Supreme Court
Drug: Lipitor, cholesterol treatment
Status: Awaiting decision on cert petition

The district court dismissed claims that Pfizer Inc. paid off Ranbaxy to delay its launch of generic Lipitor by forgiving some damages Ranbaxy owed in a separate case over Accupril, a blood pressure medication. The court concluded that the plaintiffs' claims couldn't go forward because they didn't reasonably estimate the cash value of the settlement and thus couldn't qualify as plausible.

. . .

Case: In re: Loestrin 24 Fe Antitrust Litigation
Court: District of Rhode Island
Drug: Loestrin, oral contraceptive
Status: Discovery

In this case, drug purchasers claim that Warner Chilcott PLC signed a series of anti-competitive deals with Watson Pharmaceuticals Inc. and Lupin Pharmaceuticals Inc. that settled litigation over Loestrin and another oral contraceptive with a variety of early entry dates and exclusive sales rights. The deals also gave the generics makers rights to market other Warner products through side agreements.

To access the full article, click here.

Cohen Milstein is a member of the Plaintiffs' Executive Committee in In re Solodyn Antitrust Litigation, Co-Lead Counsel for a proposed class of indirect purchasers in In re Lipitor Antitrust Litigation, and Co-Lead Counsel for the proposed class of indirect purchasers in In re Loestrin 24 Fe Antitrust Litigation.